Table 1.
Demographic and clinical characteristics, laboratory findings and in-hospital course of the general population with COVID-19 and in the two subgroups according to the occurrence of new onset atrial fibrillation (NOAF) during hospital stay.
| NOAF during hospitalization |
|||
|---|---|---|---|
| Yes | No | P value | |
| Number of patients | 33 (%5) | 625 (94.9) | – |
| Age, years | 72.42 ± 6.10 | 53.78 ± 13.80 | <0.001 |
| Gender, female, n | 17 (%51.5) | 269 (%43) | 0.338 |
| Diabetes Mellitus, n | 7 (%21.2) | 112 (%17.9) | 0.632 |
| Hypertension, n | 22 (%66.6) | 188 (%30) | <0.001 |
| Vascular disease, n | 6 (%18.1) | 91 (%14.5) | 0.567 |
| Heart Failure, n | 9 (%27.2) | 40 (%6.4) | <0.001 |
| Stroke/transient ischemic attack, n | 0 | 7 (%1) | 0.541 |
| Smoking, n | 6 (%18) | 74 (%12) | 0.277 |
| COPD/ Asthma, n | 7 (%21) | 104 (%16) | 0.497 |
| Family history of atrial fibrillation | 0 | 4 (%0.6) | 0.645 |
| Valvular heart diseases, | 2 (%6) | 17 (%2.7) | 0.264 |
| Previous episodes of CAP | 3 (%9) | 68 (%10.8) | 0.532 |
| CHA2DS2-VASc | 3.42 ± 0.56 | 1.36 ± 1.27 | <0.001 |
NOAF: new onset atrial fibrillation.
COPD: chronic obstructive pulmonary disease.
PAF: paroxysmal atrial fibrillation.
CAP: Community-acquired pneumonia.
CHA2DS2-VASc: Congestive heart failure/left ventricular dysfunction, Hypertension, Age (≥ 75 years 2 points), Diabetes, Stroke/transient ischemic attack (2 points), Vascular disease, Sex category.